Digoxin in Heart Failure

Mechanism of Action

1. Inhibition of Na+/K+-ATPase on cardiac myocytes - raises intracellular Na+, which reduces Na+/Ca2+ exchange activity, increasing intracellular calcium and thereby enhancing myocardial contractility (positive inotropy).
2. Sensitization of vagal afferent nerves - inhibits Na+/K+-ATPase in vagal afferents, increasing vagal tone. This counterbalances the heightened adrenergic activation seen in advanced heart failure and slows AV conduction. This is now considered the primary mechanism in HF, rather than the inotropic effect.
3. Renal effects - inhibits tubular Na+/K+-ATPase, mildly blunting sodium reabsorption.

• Braunwald's Heart Disease, Cardiac Glycosides section

Clinical Evidence: The DIG Trial

• Result: Digoxin had a neutral effect on all-cause mortality but significantly reduced HF hospitalizations and favorably affected the combined endpoint of death or hospitalization for worsening HF.
• A trend toward decreased deaths from pump failure (p = 0.06) was offset by increased sudden and non-pump failure cardiac deaths (p = 0.04).
• Serum level is critical: Trough levels of 0.5-1.0 ng/mL are recommended. In men, levels of 0.6-0.8 ng/mL were associated with decreased mortality.
• Sex difference: A post-hoc analysis showed digoxin was associated with a ~23% higher all-cause mortality in women (not men), possibly due to weight-based dosing rather than trough level-based dosing.
• The DIG trial was conducted before widespread beta-blocker use; no large trial with contemporary GDMT (ACEi + beta-blocker + MRA + SGLT2i) exists.
• Braunwald's Heart Disease, p. 160-161

Rational Use in Heart Failure

Indications

Where Digoxin Fits in the Treatment Ladder

1. First-line (guideline-directed medical therapy): ACEi/ARB or ARNi + beta-blocker + MRA + SGLT2i/2 inhibitor
2. Digoxin is second/third-line: Added only when patients remain symptomatic on optimized GDMT, primarily to reduce hospitalizations.
3. It does not reduce mortality and should never replace the four pillars of HFrEF therapy.

Dosing

• Standard maintenance dose: 0.125 mg/day (the dose of choice for most patients)
• Higher doses (0.25 mg/day) are rarely used and not recommended for HF in sinus rhythm or AF
• Target serum trough level: < 1.0 ng/mL (ideally 0.5-0.8 ng/mL)
• Dose must be adjusted for renal function (renally cleared): CL = 0.88 × CrCl + 0.33 mL/min/kg
• Oral bioavailability ~70%; therapeutic index is narrow (~2-3x)
• Goodman & Gilman's Pharmacological Basis, Box 2-4

Adverse Effects and Toxicity

Factors that Increase Toxicity Risk

• Hypokalemia (most important - digoxin and K+ compete for the same ATPase binding site)
• Renal impairment (reduced clearance)
• Drug interactions: quinidine, verapamil, spironolactone, flecainide, propafenone, amiodarone all raise serum digoxin levels
• Elderly patients and women (lower lean body mass)
• Patients with advanced heart block (contraindicated without a pacemaker)

Treatment of Toxicity

• Purified Digoxin-specific Fab fragments (Digibind/DigiFab) for life-threatening toxicity - rapidly reverses toxicity
• Monitor serum K+ carefully, especially with concomitant aldosterone antagonists
• Braunwald's Heart Disease, p. 161

Current Perspective (2024-2026)

• A 2023 systematic review/meta-analysis in Curr Drug Targets specifically examined digoxin in HFpEF and found no clear benefit - it is generally not recommended in preserved ejection fraction HF.
• The 2024 JACC Heart Failure network meta-analysis of pharmacological treatments in HFmrEF/HFpEF similarly does not support digoxin in these populations.
• A 2025 expert consensus on digoxin toxicity highlights that toxicity remains a significant clinical concern and requires careful therapeutic drug monitoring.
• Overall use is declining due to equivocal trial data and the dominance of GDMT with mortality benefit.

Summary: Key Points for Rational Use

Digoxin in Heart Failure - Katzung's Basic & Clinical Pharmacology (16th Ed.)

Chemistry

Pharmacokinetics

• Katzung, Chapter 13

Pharmacodynamics

A. Molecular Mechanism

1. Na+/K+-ATPase inhibition → ↑ intracellular Na+
2. ↑ intracellular Na+ → reduced Ca2+ expulsion via Na+/Ca2+ exchanger (NCX) → ↑ intracellular Ca2+ → Ca2+ stored in SR → released during systole → ↑ contractility

Note: An endogenous digitalis-like steroid (possibly ouabain or marinobufagenin) is hypothesized to exist, given the highly conserved receptor on Na+/K+-ATPase.

B. Mechanical Effects (Figure 13-5)

• Increased rate of tension development and relaxation
• Little or no change in time to peak tension
• Increased contractility in both normal and failing myocardium

C. Electrical Effects (Table 13-2 from Katzung)

• Therapeutic doses: Cardioselective parasympathomimetic effect (vagal stimulation, baroreceptor sensitization, muscarinic facilitation) - primarily affects atria and AV node
• Toxic doses: ↑ sympathetic outflow - exaggerates all toxic effects

D. Interactions with Electrolytes

• Katzung, Chapter 13

E. Extracardiac Effects

Clinical Pharmacology: Rational Use of Digitalis in HF

Indication

• HF + atrial fibrillation (primary indication)
• Symptomatic HFrEF - only when diuretics and ACE inhibitors have failed to control symptoms

"Only about 50% of patients with normal sinus rhythm (usually those with documented systolic dysfunction) will have relief of heart failure from digitalis." - Katzung, Ch. 13

Dosing

• Mortality is reduced at serum digoxin concentrations < 0.9 ng/mL
• Mortality is increased at concentrations > 1.5 ng/mL
• Higher concentrations may be needed in AF for rate control

What Digoxin Does and Does NOT Do

Katzung: "Although the net effect of the drug on mortality is mixed, it reduces hospitalization and deaths from progressive heart failure at the expense of an increase in sudden death."

Place in Therapy (ACC/AHA Stage C)

1. Diuretics (furosemide, SGLT2 inhibitors) - first-line for congestion
2. ACE inhibitors / ARBs / ARNIs - reduce preload, afterload, remodeling
3. Beta-blockers (bisoprolol, carvedilol, metoprolol, nebivolol) - reduce mortality
4. Aldosterone antagonists (spironolactone, eplerenone) - reduce mortality
5. Digoxin - add when symptoms persist despite the above; primarily to reduce hospitalizations and for HF + AF

Summary Table (from Katzung Chapter 13)

• Katzung's Basic and Clinical Pharmacology, 16th Ed., Chapter 13